#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Systemic mastocytosis Central nervous system neoplasm Oesophageal adenocarcinoma stage II Anal squamous cell carcinoma Colorectal cancer metastatic Haemophilia Cystic fibrosis lung Sickle cell disease Neuroendocrine cell hyperplasia of infancy Leukaemia Polymyositis Hypereosinophilic syndrome Fibrosarcoma metastatic Fibrous dysplasia of bone Neuroendocrine carcinoma More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Diagnostics Lymphatic malformation – Diagnostics Extranodal marginal zone B-cell lymphoma (MALT type) – Treatment Mucopolysaccharidosis I – Trials in Disease CADASIL – Basic Information Myelodysplastic syndrome with excess blasts – Diagnostics Waldenstrom’s macroglobulinaemia refractory Angiosarcoma non-metastatic – Life with Disease Hereditary motor and sensory neuropathy – Trials in Disease Sarcoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sodium Chloride Leflunomide Human Serum Albumin Mitotane Desvenlafaxine Benzoate Metoprolol Succinate Varenicline CILOSTAZOL ISPAGHULA HUSK Tetracaine Hydrochloride Reboxetine Capivasertib Calcium Polystyrene Sulfonate Kd050 Benzathine Benzylpenicillin Levofloxacin Alizapride Lidocaine Hydrochloride HSP-CAR30 Atacicept More therapies…

    Learn about Your Condition

    Appendicitis Immunodeficiency congenital Gastrointestinal disorder PIK3CA-activated mutation Biliary adenoma Respiratory failure Aortic valve stenosis Colorectal adenoma Adrenocortical carcinoma Phaeochromocytoma Perineal injury Ischaemic skin ulcer Niemann-Pick disease KBG syndrome Follicular lymphoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic lymphocytic leukaemia recurrent

  • A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    Investigated Drugs:
    • Acalabrutinib
    • Venetoclax
    Austria Czechia Ireland Italy Poland Spain

  • Study of NX-5948 in adults with relapsed or resistant chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received BTK inhibitor and BCL-2 inhibitor treatment

    Recruiting

    2 1 1
    France Hungary Italy Poland

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Follicular lymphoma stage II
    • Follicular lymphoma stage III
    • Marginal zone lymphoma refractory
    Investigated Drugs:
    • BGB-16673
    • Mosunetuzumab
    • Glofitamab
    Germany Italy Poland

  • Study on Venetoclax and Obinutuzumab for Adults with Recurring Chronic Lymphocytic Leukemia

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Obinutuzumab
    • Venetoclax
    Austria Bulgaria Germany Italy Romania Spain

  • Long-Term Safety Study of MB-CART19.1, MB-CART20.1, and Zamtocabtagene Autoleucel for Patients with Advanced Melanoma or B-Cell Malignancies

    Recruiting

    1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Acute lymphocytic leukaemia recurrent
    Investigated Drugs:
    • Mb-Cart20.1
    • Autologous T-Cells Transduced With Lentiviral Vector Expressing A Chimeric Antigen Receptor Directed Against Cd19
    • Zamtocabtagene Autoleucel
    Germany

  • Study of venetoclax plus rituximab in adult patients with relapsed chronic lymphocytic leukemia (CLL) in Poland

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Rituximab
    • Venetoclax
    Poland
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!